Patient-derived sarcoma xenografts for individual-patient selection of chemotherapy—ready for prime time?

Authors

  • Andrew J. Wagner MD, PhD

    Corresponding author
    1. Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts
    • Corresponding author: Andrew J. Wagner, MD, PhD, Center for Sarcoma and Bone Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, MA 02215; Fax: (617) 632-3408; awagner@partners.org

    Search for more papers by this author

  • See referenced Original Article on pages 2006–2015, this issue.

Abstract

Patient-derived sarcoma tumor xenografts can be successfully grown in mice and tested for sensitivity to chemotherapy regimens. Are these tests ready to guide patient care?

Ancillary